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Abstract
Background: Low levels of serum selenium are associated with increased risk of mortality among HIV+ patients in
East Africa. We aim to assess the effect of selenium supplementation on CD4 cell count, HIV viral load,
opportunistic infections, and quality of life in HIV-infected patients in Rwanda.
Methods and Design: A 24-month, multi-centre, patient and provider-blinded, randomized, placebo-controlled clinical
trial involving 300 pre-antiretroviral therapy (ART) HIV-infected patients will be carried out at two sites in Rwanda. Patients
≥ 21 years of age with documented HIV infection, CD4 cell count of 400-650 cells/mm
3, and not yet on ART will be
recruited. Patients will be randomized at each study site using a randomized block design to receive either the selenium
micronutrient supplement or an identically appearing placebo taken once daily. The primary outcome is a composite of
time from baseline to reduction of CD4 T lymphocyte count below 350 cells/mm
3 (confirmed by two measures at least
one week apart), or start of ART, or the emergence of a documented CDC-defined AIDS-defining illness. An intention-to-
treat analysis will be conducted using stepwise regression and structural equation modeling.
Discussion: Micronutrient interventions that aim to improve CD4 cell count, decrease opportunistic infections,
decrease HIV viral load, and ultimately delay initiation of more costly ART may be beneficial, particularly in
resource-constrained settings, such as sub-Saharan Africa. Additional trials are needed to determine if micro-
supplementation can delay the need for more costly ART among HIV-infected patients. If shown to be effective,
selenium supplementation may be of public health importance to HIV-infected populations, particularly in sub-
Saharan Africa and other resource-constrained settings.
Trial Registration: NCT01327755
Background
In sub-Saharan Africa, more than 30 million people are
living with HIV/AIDS, malnutrition and food insecurity
are endemic [1] HIV infection compromises the nutri-
tional status of infected individuals and poor nutritional
status can enhance progression of the disease [2]. The
relationship between immune function and nutritional
supplementation has been well described [3-6]. Studies
have reported a high prevalence of nutrient deficiencies
early in the course of HIV infection [7-9].
It is well understood that micronutrient deficiencies
and HIV disease progression aggravate each other
[10,11]. Among HIV-infected persons not receiving anti-
retroviral therapy (ART), observational studies have
shown that low or deficient serum concentrations of
several micronutrients are associated with low CD4 cell
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gression, or HIV-related mortality [12-26]. Selenium is
one essential nutrient necessary for endogenous antioxi-
dant defense. Selenium deficiency, as indicated by low
plasma selenium concentrations, is common among
HIV-infected individuals [27,28].
While many observational studies on selenium in HIV-
infected patients have been conducted in developed coun-
tries over the past decade, few have been conducted in sub-
Saharan Africa. Clinical trial data on selenium supplemen-
tation is also limited in both developed and developing
countries. There are two recent high-impact randomized
clinical trials (RCTs) that have been conducted to assess
the individual association of selenium supplementation on
HIV viral load and CD4 cell count. The first trial, con-
ducted in Miami by Hurwitz et al [29], found that selenium
supplementation of 200 μg daily significantly suppressed
the progression of HIV viral load and improved CD4 cell
count after 9 months of treatment. The second trial, con-
ducted in Tanzania by Kupka et al [30], found that sele-
nium supplementation of 200 μg daily provided to HIV-
infected pregnant women before and after pregnancy
(between 12 and 27 weeks of gestation and 6 months after
birth) had no significant effect on HIV viral load or CD4
cell count, but did significantly lower risk of infant death.
Although the results of these two clinical trials appear
to contradict, it is important to recognize the inherent
differences in their design, setting, and populations
under study. Additional evidence from other settings
and populations is still required to more accurately
determine the effect of selenium supplementation on
HIV viral load and CD4 cell count in HIV-infected indi-
viduals. Therefore, we have designed a randomized trial
to examine the effect of selenium supplementation on
CD4 cell counts in HIV-infected patients who are not
yet on ART. This trial will take place in Rwanda, where
an estimated 250,000 adults and children are living with
HIV [31], of which only 50,000 are receiving ART [32].
Methods and Design
Funding
Global Benefit has sponsored this trial. The trial sponsors
and investigators will make financial assurance statements
to the concerned bodies (Ministry of Health’sN a t i o n a l
Ethics Commission, National Research Commission) on
the availability of funds for the completion of the trial.
Registration
This trial has been registered with ClinicalTrials.gov.
The registration number is NCT01327755.
Study Design
This study is a 24-month, multi-centre, patient, provider
and analyst-blinded, randomized, placebo-controlled
clinical trial involving 300 pre-ART HIV-infected
patients in Rwanda. (See Figure 1 for a study flow
diagram.)
Objectives and Hypothesis
The primary outcome of the study is time from baseline
to reduction of CD4 T lymphocyte count below 350
cells/mm
3 (confirmed by two measures at least one
week apart), or start of ART, or the emergence of a
documented CDC-defined AIDS-defining illness. We
hypothesize that selenium supplementation in pre-ART
patients will improve CD4 cell counts, decrease oppor-
tunistic infections, decrease HIV viral load, and delay
ART initiation.
Setting and Participants
Patients will be recruited at two purposely-selected
health facilities that offer care and treatment for HIV/
AIDS patients in Rwanda. These facilities have been
chosen due to the feasibility of recruiting all patients
within a 3-4 month period and the feasibility of
coordination.
Patient eligibility will be restricted to HIV-infected
adults 21 years of age and older at study enrolment.
Only patients not yet eligible for ART will be included.
Only patients with CD4 cell count between 400 and 650
cells/mm
3 will be selected because they are at similar
immunological level and hence they will not be eligible
to start ART treatment at the start of the study. Eligible
participants must also be willing to practice a barrier
method of birth control at all times. Written informed
consent will be required from patients to participate in
this study.
Eligible patients will be identified from patient regis-
ters. These patients will be informed about the study
during a regular scheduled clinic visit or through home
visits by site staff not otherwise involved in data collec-
tion. Patients who are interested in the study will be
provided with further details and consent procedures.
Those fitting the inclusion criteria will be enrolled and
followed for 2 years. Study assessments will occur at
baseline, 6, 12, 18, and 24 months.
Patients will be excluded if they are intending to be
transferred out of the clinic catchment area before study
ends and/or if they are scheduled to start ART. Mori-
bund patients, pregnant women, and those unable or
not wanting to commit to barrier method of birth con-
trol will also be excluded.
Randomization
Participants will be randomized using a simple rando-
mized block design to receive either selenium or an iden-
tically appearing placebo to be taken once daily for 24
months. The Rwandan Ministry of Health recommends
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bination of trimethoprium and sulfamethoxazole used for
the treatment of a variety of bacterial infections, for all
HIV-infected patients. Therefore, all participants will also
receive co-trimoxazole irrespective of experimental
assignment. Participants who do not return to the clinic
as scheduled will be followed up at home.
Study participants will be identified by a unique study
identification number. The randomization schedule will be
prepared by the product manufacturer, Seroyal, and the
randomization sequence will be concealed from the study
investigators and providers. Study participants will be
assigned a specific allocation number. An unblinding list
will be kept at the site of the manufacturer and will be
provided as needed to the Data and Safety Monitoring
Officer (DS). Site study personnel (investigator and clinical
personnel monitoring the safety and laboratory assay
results) and study participants will be blinded with respect
to the allocation. Unblinding of an individual study partici-
pant will be indicated in the event of a medical emergency
where the clinical management/medical treatment of the
study participant could be altered by knowledge of the
group assignment allocation of the investigational product.
Intervention
The trial intervention will consist of capsules containing
200 mcg of selenium in the form of selenium yeast,
which contains selenomethionine. Capsules will be
              
Participant recruitment 
v From 2 purposely-selected 
health facilities
Eligibility assessment
v Confirmed HIV infection
v Age 21 years and older
v CD4 cell count 400-650 
cells/mm
3
v Not yet on ART
Randomization
Selenium 200mcg daily
Exclusion criteria
v Not meeting inclusion 
criteria
v Intending to be 
transferred out of the 
clinic catchment 
v Scheduled to start 
ART
v Moribund, pregnant, 
unable or not wanting 
to commit to barrier 
method of birth 
control
Baseline data collection
v Baseline questionnaire
v Clinical assessment
v CD4 cell count
v HIV viral load
Baseline data collection
v Baseline questionnaire
v Clinical assessment
v CD4 cell count
v HIV viral load
Allocation Placebo
Baseline 
assessment
Enrollment
Follow-up
assessments
Follow-up (6, 12, 18, 24 
months)
v Follow-up questionnaire
v Clinical assessment
v CD4 cell count
v HIV viral load
Follow-up (6, 12, 18, 24 
months)
v Follow-up questionnaire
v Clinical assessment
v CD4 cell count
v HIV viral load
Target enrollment n=300 
(assuming 25% relative 
risk reduction, 221 
patients need to be 
randomized)
Figure 1 Study flow diagram. This figure displays the intended recruitment and measurement points in this trial.
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cipants will be instructed to take one capsule daily. Sele-
nium will be stored in a dry cool location during the
course of the trial. Shelf life of the product is well
beyond the two-year time period expected for the trial
duration. To ensure optimal adherence, participants will
receive adherence counseling at baseline and when pick-
ing up refills on a monthly basis. Additional adherence
counseling will be provided to patients who have sub-
optimal adherence.
Selenium capsules are supplied by Seroyal, a Canadian
Nutraceutical company. The sponsors of the trial and
the investigators will be responsible for ensuring that
the investigational pharmaceutical product is safe. Com-
parator products (placebo) supplied for the clinical trial
will be of proven quality and will be available to be veri-
fied by the National Bureau of Standards. Records will
be kept of information about the shipment, delivery,
receipt, storage, return, and destruction of any remain-
ing pharmaceutical products. The investigators will not
supply the investigational product to any person not tar-
geted to receive it.
Outcomes
T h ep r i m a r yo u t c o m eo ft h es t u d yi sac o m p o s i t eo u t -
come involving reduction of CD4 T lymphocyte count
to below 350 cells/mm
3 (confirmed by two measures at
least one week apart), or start of ART, or the emergence
of a documented CDC-defined AIDS-defining illness.
Secondary outcomes includes viral suppression at 6, 12,
18, and 24 months; quality of life; weight gain; presence
of opportunistic infections and mortality.
Measurement of Outcomes and Other Variables of
Interest
Patient Interviews
Trained nurses will use a structured questionnaire to
collect data on patients’ demographics at baseline. Addi-
tionally, at baseline and at each follow-up visit, a ques-
tionnaire will be used to collect information on
psychosocial factors, access to care and treatment, atti-
tudes towards and experiences with the supplementa-
tion, quality of life, self-efficacy, nutrition, opportunistic
infections, and adherence to the study protocol. The
questionnaire will be available in English and Kinyar-
wanda. Nurses will also use a data abstraction tool at
baseline and at each follow-up visit to obtain informa-
tion on height, weight, blood pressure and other clini-
cally relevant information.
HIV Viral Load and CD4 Cell Count
At baseline, and at month 6, 12, 18 and 24, blood draws
will be done for assessment of CD4 cell count and HIV
viral load. Blood samples will be collected into EDTA
tubes (Becton Dickinson, San Jose, CA, USA). The viral
load samples will be transported and analyzed at the
National Reference Laboratory within 4 hours; plasma
will be separated from cells by centrifugation at 200 g,
aliquoted and stored at -70°C until the real time PCR
will be performed using Cobas TaqMan 48 (Roche Diag-
nostic Systems, NJ, USA) that has a detection limit of 40
R N Ac o p i e s / m l .T h eR N Aw i l lb ee x t r a c t e df r o mt h e
plasma with chloroform, followed by alcohol precipita-
tion and dilution with the HIV Monitor specimen dilu-
ent (100 μl). Amplification and detection of the
extracted RNA (40 μl) will be performed in accordance
with the manufacturer’s instructions. CD4 cell count
will be measured at the National Reference Lab, or the
site laboratory, using FACS Count (Becton Dickinson
immunocytometry).
Sample Size Calculation
We chose our CD4 depletion event rate based on the
work of the CASCADE cohort which displays an average
CD4 depletion of 114 (32-229) cells/μl per year and
where 54% of individuals had a decline > 100 cells/μl
per year if CD4 evaluations were rare, as in Rwanda
[33]. We expect that the majority of participants in our
study, about 60%, will enter the study with a CD4 at
risk of reaching 350 cells/μl within the first year as most
evidence demonstrates that patients in East Africa initi-
ate treatment due to symptomatic HIV with a median
C D 4o f1 4 1t o1 6 9( d e p e n d i n go ns o u r c e ) .T h u s ,
patients with a high CD4 will be somewhat more rare to
enroll [34,35].
We applied several sample sizes to display that even
small changes in the relative risk of the intervention will
yield a large impact on the required sample size (see
Table 1). Our three sample size assumptions are based
on the likelihood of an intervention delivering a small,
moderate or large effect (relative risk reduction of 10,
25, and 50%). Given that we do not have strong evi-
dence from previously completed trials, we are assuming
the event of depleting CD4 status will occur in 60% of
control patients at one year and 60% of experimental
patients at one year if the intervention delivers no effect.
Table 1 provides the estimates required for power of
80% and an alpha of 0.05.
We employed several methods to make these calcula-
tions. The below estimates are based on Markov Chain
Monte Carlo Methods whereby we explored the impact
Table 1 Sample Size Calculation estimates
RRR Control event
rate
Experimental event
rate
Sample
size
Power
10% 60% 55% 2312 80%
25% 60% 44% 314 80%
50% 60% 29% 76 80%
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the differing possible risks of an underlying disease
event. We performed 5,000 simulations for each esti-
mate. As we employ informed estimates, using a Baye-
sian profile, our estimates may differ slightly compared
with other software approaches. However, they should
not differ to an important amount.
Based on these calculations and our resources, we aim
to enroll 300 patients in the trial. This leads to an RRR
slightly lower than 25% and represents a very important
reduction in events. Recognizing that no single trial can
provide definitive evidence of effectiveness, this trial will
contribute to the overall evidence of selenium supple-
mentation for CD4 maintenance [36,37]. If control
patients demonstrate lower rates of compliance to the
intervention due to a lack of effects of, say, 20%, the
power is increased to 96% and an alfa of 0.25. At the
conclusion of our trial, we will conduct a meta-analysis
to determine the overall power that current evidence
contributes to answering this clinical question.
Analysis Plan
Analysis will be conducted jointly by the study team in
Rwanda and in Canada using standard statistical software.
The analysis and reporting of the results with follow the
CONSORT guidelines [38]. The statistician/data analyst
will be blinded to the study group. The process of patient
selection and flow throughout the study will be summar-
ized using a flow-diagram (See Figure 1). The analysis
results of patient demographics and baseline outcome
variables (both primary and secondary) will be summar-
ized using descriptive summary measures: expressed as
mean (standard deviation) or median (minimum-maxi-
mum) for continuous variables and number (percent) for
categorical variables. We will adopt an intention-to-treat
principle to analyze all outcomes, meaning that data from
participants will be analyzed according to the group to
which they were randomized even if they do not receive
the allocated intervention. We will also use multiple-impu-
tation to handle missing data. We will use the T-test for
comparing groups on continuous outcomes and the chi-
squared test for binary outcomes. We will consider a
threshold of 0.05 as statistical significance. For all group
comparisons, the results will be expressed as effect (risk
ratio for binary outcomes), corresponding two-sided 95%
confidence intervals and associated p-values. P-values will
be reported to three decimal places with values less than
0.001 reported as < 0.001. Because the primary outcome is
a composite outcome, we will assess heterogeneity
between the included outcomes [39,40]. Further, adjusted
analyses using the following baseline covariates (age, gen-
der, nutritional status) will be performed using regression
techniques to investigate the residual impact of key base-
line characteristics on the outcomes. Goodness-of-fit will
be assessed by examining the residuals for model assump-
tions and chi-squared test of goodness-of-fit. All analyses
will be performed by a professional statistician.
Adverse Events
This study will use the standard level of expedited
adverse event (AE) reporting as defined in the Division
of AIDS (DAIDS) AE Manual. At this level, this study
will report all AEs following any exposure to the investi-
gational product. AE follow-up will be reported on a
standardized form during the protocol-defined AE
reporting period, which will be the entire study duration
for an individual participant (from study enrollment
until study completion or study discontinuation of a
participant for any reason). After the end of the proto-
col-defined AE reporting period, sites will report serious,
unexpected, clinical suspected adverse drug reactions or
if the study site staff becomes aware of the event on a
passive basis (e.g. from publicly available information).
AEs will be managed in accordance with good medical
practices by the clinical study team who will assess and
treat the study participant as appropriate, including referral.
All study participants experiencing AEs, regardless of sever-
ity, will be followed until satisfactory resolution, return to
baseline, or until the toxicity is presumed to be irreversible.
If at the end of the study, an AE (including clinically signifi-
cant lab abnormality) which is considered possibly, prob-
ably or definitely related to the investigational product is
unresolved, follow-up will continue until resolution if possi-
ble and the study participant will be referred. If treatment
and medical care is required as a result of harm caused by
the investigational product or study procedures, this will be
provided free of charge to the participant.
Ethical Considerations
This trial will be conducted in compliance with the protocol
approved by the institutional review boards of the Canadian
College of Naturopathic Medicine and Wilfred Laurier Uni-
versity in Canada, and the National Ethics Committee
(NEC) in Rwanda. No deviation from the protocol will be
implemented without the prior review and approval of the
I R Be x c e p tw h e r ei tm a yb en ecessary to eliminate an
immediate hazard to a participant. In such case, the devia-
tion will be reported to the IRB as soon as possible.
A signed consent form will be obtained from each
participant. The consent form describes the purpose of
the trial, the procedures to be followed and the risks
and benefits of participation. A copy of the consent
form will be offered to the participant. Trial participants
will receive 1,000 Rwandan Francs (equivalent to ~ $
1.67 US dollars) per month for their travel to and from
the clinic for interviews, lab work-up and picking up
their supplement. In addition to this compensation, in
the event that the study shows benefit, Global Benefit
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mentation to all participants in the trial for a period of
at least one year following study completion.
Quality Control and Quality Assurance
The sponsor and investigators will be responsible for
implementing and maintaining quality assurance and
quality control systems with written standard operating
procedures to ensure that the trial is conducted and data
are generated, documented, and reported in compliance
with the protocol, good clinical practice, and the applic-
able regulatory requirements. The sponsor will also be
responsible for securing agreement from all involved par-
ties to ensure direct access to all trial related sites, source
data and documents, and reports for the purpose of mon-
itoring and auditing by the sponsor, and inspection by
domestic and foreign regulatory authorities.
Discussion
Micronutrient interventions that aim to improve CD4
cell count, decrease opportunistic infections, decrease
HIV viral load, and ultimately delay initiation of more
costly ART may be beneficial, particularly in resource-
constrained settings, such as sub-Saharan Africa. It has
been shown that selenium is deficient in HIV-infected
populations [27,28]. For instance, a study conducted
among HIV-infected children in Rwanda found that
close to 40% had sub-optimal levels of selenium [41].
Data assessing the efficacy of selenium supplementation
in randomized controlled trials is limited. Additional
trials are needed to determine if selenium supplementa-
tion can delay the need for ART among HIV-infected
patients. If shown to be effective, selenium supplementa-
tion may be of great public health importance to HIV-
infected populations, particularly in sub-Saharan Africa
and other resource-constrained settings.
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